Clarametyx Biosciences, Columbus, OH, USA
ESKAPE pathogens, polymicrobial biofilms
Clarametyx’s therapy, CMTX-101, is a monoclonal antibody designed to rapidly collapse bacterial biofilms – protective shields that coat bacterial pathogens and help make them resistant to the effects of antibiotics and immune response. CMTX-101 targets a region of DNABII binding proteins that are generally identical across all pathogenic bacteria. Bacterial DNABII proteins stabilize and maintain the integrity of bacterial biofilms. Precisely targeting this region on the DNABII proteins rapidly collapses biofilms, removing the protective shield. CMTX-101 is in development for the treatment of moderate-to-severe pneumonia through co-administration with standard antibiotic regimens. CMTX-001 acts on biofilms formed by multiple bacterial pathogens, including all ESKAPE pathogens and polymicrobial biofilms.
Current Development Stage: Pre-clinical
CARB-X Investment: Initial investment of up to $2.42m, with potential option payments up to $11.85m.
Initial CARB-X Investment Date: July 1, 2020